Physician profile
Miles Cobia
NPI 1467830117
$27,669.47
in general payments reported to CMS, 2019-2025
11 companies · $7,197 in 2025
The $7,197 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.29 · 2021: $11.11 · 2022: $118 · 2023: $13K · 2024: $7,056 · 2025: $7,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,319.89 |
| Food and Beverage | $1,203.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $26,929.50 | 2023-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Abbvie INC. | $281.93 | 2024-2025 | |
| Medtronic, INC. | $145.38 | 2022-2023 | Linq II |
| Chiesi USA, INC. | $137.95 | 2024 | Cleviprex |
| Cycle Pharmaceuticals INC | $50.45 | 2024-2025 | Tascenso Odt, Bafiertam |
| Ucb, INC. | $32.86 | 2024 | Nayzilam |
| Lilly USA, LLC | $23.63 | 2025 | Kisunla |
| E.R. Squibb & Sons, L.L.C. | $21.16 | 2024 | Eliquis |
| Boston Scientific Corporation | $18.21 | 2023 | |
| Sk Life Science, INC. | $17.29 | 2020 | |
| Amgen INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Cobia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.